Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals announced the grant of non-qualified stock options to purchase an aggregate of 191,000 shares of its common stock to two newly hired employees. These options were granted on June 1, 2026, under the 2022 Employment Inducement Incentive Award Plan, with an exercise price of $3.98 per share. The options have a 10-year term and will vest over four years, subject to continued employment.

Zentalis Pharmaceuticals, Inc. announced the appointment of Shannon Campbell to its Board of Directors, effective May 22, 2026. The Board's size increased from six to seven directors. Ms. Campbell will serve as a Class I director until the 2027 Annual Meeting and has also been appointed to the Compensation Committee. Her compensation includes an annual retainer of $45,000 for Board service and an additional $7,500 for committee service, along with an initial grant of 114,200 restricted stock units and future annual equity grants.

Zentalis Pharmaceuticals announced the appointments of Shannon Campbell to its Board of Directors and Sarah Kelly as Senior Vice President of Commercial Strategy. These strategic hires aim to bolster the company's commercial and operational capabilities as it advances its registrational program for azenosertib, a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. The company is preparing for potential commercialization, with a DENALI Phase 2 trial readout expected by year-end 2026 and a Phase 3 confirmatory trial underway.

Zentalis Pharmaceuticals announced positive data from Part 1 of its Phase 1b MUIR trial, evaluating azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer (PROC). The combination demonstrated encouraging clinical activity with an overall response rate (ORR) of 39% and a median progression-free survival (PFS) of 7.3 months across all dose cohorts. Notably, the 250 mg intermittent dose cohort achieved a 50% ORR and 9.2-month median duration of response, along with a manageable safety profile. These results, which will be presented at ASCO 2026, support further evaluation of azenosertib-taxane combinations in ovarian cancer and other tumor types.

Zentalis Pharmaceuticals announced that data from Part 1 of its Phase 1b MUIR trial for azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer (PROC) will be presented at the 2026 ASCO Annual Meeting. The trial showed encouraging clinical activity in an all-comer PROC population, with an Overall Response Rate (ORR) of 39.1% and a median Progression-Free Survival (PFS) of 7.3 months. The combination demonstrated a manageable safety profile with a low rate of high-grade adverse events, suggesting broad potential for azenosertib.

Zentalis Pharmaceuticals announced that its management team will participate in four upcoming investor conferences in May and June 2026. These include the H.C. Wainwright 4th Annual BioConnect Conference, Stifel 2026 Virtual Oncology Forum, TD Cowen 6th Annual Oncology Innovation Summit, and Jefferies Global Healthcare Conference. The company will hold fireside discussions at each event, with webcasts available on its investor relations website.

Zentalis Pharmaceuticals reported a net loss of $35.35 million for the first quarter of 2026, a significant improvement from the $48.28 million net loss in the same period last year, primarily due to the absence of restructuring charges. Research and development expenses increased by 5.4% to $28.72 million, reflecting continued investment in its lead product candidate, azenosertib. The company ended the quarter with $211.8 million in cash, cash equivalents, and marketable securities, but noted it will require substantial additional capital to fund its operations.

Zentalis Pharmaceuticals reported a net loss of $(35.35) million, or $(0.50) per share, for Q1 2026, an improvement from $(48.28) million in Q1 2025. The company ended the quarter with $211.8 million in cash, providing a runway into late 2027. Key clinical progress includes the selection of 400mg QD 5:2 as the pivotal dose for azenosertib monotherapy in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and the initiation of the ASPENOVA Phase 3 confirmatory trial. The DENALI Phase 2 trial's topline readout is expected by year-end 2026, potentially supporting accelerated approval.

Zentalis Pharmaceuticals announced the dosing of the first patient in its global Phase 3 ASPENOVA clinical trial for azenosertib, targeting Cyclin E1-positive platinum-resistant ovarian cancer (PROC). This randomized, confirmatory trial aims to enroll approximately 420 patients, comparing azenosertib monotherapy to standard-of-care chemotherapy. The trial is part of a dual-track regulatory strategy, with the ongoing DENALI Phase 2 trial pursuing accelerated approval and ASPENOVA designed to support full approval, with its design aligned with FDA requirements. Azenosertib, a WEE1 inhibitor, has Fast Track Designation and targets a biomarker-selected population representing about 50% of PROC patients.

Zentalis Pharmaceuticals, Inc. announced that its Compensation Committee granted non-qualified stock options to purchase 26,000 shares of common stock to one newly hired employee on May 1, 2026. These options were issued under the 2022 Employment Inducement Incentive Award Plan as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $4.09 per share, and the options will vest over four years.